SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- May 22, 2007 -- Limerick NeuroSciences, Inc., a privately held biopharmaceutical company, announced today that it has begun the first company-sponsored clinical trial of its lead compound LNS 5310. Limerick has identified a proprietary means of improving existing therapeutics by chemically modulating bioavailability and is applying this technology to the development of safe and potent pharmaceuticals with attenuated neurotoxicity. Separately, the company announced that Corey Goodman, Ph.D., President and Chief Executive Officer of Renovis, Inc., was elected a member of the Limerick NeuroSciences Board of Directors.
